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Abstract
AIM: To evaluate daclatasvir vs  telaprevir, each 
combined with peginterferon alfa-2a/ribavirin (pegIFN/
RBV), in treatment-naive hepatitis C virus (HCV) genotype 
(GT) 1-infected patients.
METHODS: In this phase 3, randomized, open-label, 
noninferiority study, 602 patients were randomly 
assigned (2:1) to daclatasvir vs  telaprevir, stratified 
by IL28B  rs12979860 host genotype (CC vs  non-CC), 
cirrhosis status (compensated cirrhosis vs  no cirrhosis), 
and HCV GT1 subtype (GT1a vs  GT1b). Patients were 
selected by study inclusion criteria from a total of 
793 enrolled patients. Patients received daclatasvir 
60 mg once daily or telaprevir 750 mg 3 times daily 
plus pegIFN/RBV. Daclatasvir recipients received 24 
wk of daclatasvir plus pegIFN/RBV; those without an 
extended rapid virologic response (eRVR; undetectable 
HCV-RNA at weeks 4 and 12) received an additional 24 
wk of pegIFN/RBV. Telaprevir-treated patients received 
12 wk of telaprevir plus pegIFN/RBV followed by 12 
(with eRVR) or 36 (no eRVR) wk of pegIFN/RBV. The 
primary objective was to compare for noninferiority 
of sustained virologic response rates at posttreatment 
week 12 (SVR12) in GT1b-infected patients. Key 
secondary objectives were to demonstrate that the 
rates of anemia (hemoglobin < 10 g/dL) and rash-
related events, through week 12, were lower with 
daclatasvir + pegIFN/RBV than with telaprevir + 
pegIFN/RBV among GT1b-infected patients. Resis-
tance testing was performed using population-based 
sequencing of the NS5A region for all patients at 
baseline, and for patients with virologic failure or 
relapse and HCV-RNA ≥ 1000 IU/mL, to investigate 
any link between NS5A polymorphisms associated with 
daclatasvir resistance and virologic outcome. 
RESULTS: Patient demographics and disease charac-
teristics were generally balanced across treatment arms; 
however, there was a higher proportion of black/African 
Americans in the daclatasvir groups (6.0% and 8.2% 
in the GT1b and GT1a groups, respectively) than in 
the telaprevir groups (2.2% and 3.0%). Among GT1b-
infected patients, daclatasvir plus pegIFN/RBV was 
noninferior to telaprevir plus pegIFN/RBV for SVR12 
[85% (228/268) vs  81% (109/134); difference, 4.3% 
(95%CI: -3.3% to 11.9%)]. Anemia (hemoglobin < 10 
g/dL) was significantly less frequent with daclatasvir 
than with telaprevir [difference, -29.1% (95%CI: 
-38.8% to -19.4%)]. Rash-related events were also 
less common with daclatasvir than with telaprevir, but 
the difference was not statistically significant. In GT1a-
infected patients, SVR12 was 64.9% with daclatasvir 
and 69.7% with telaprevir. Among both daclatasvir 
and telaprevir treatment groups, across GT1b- or 
GT1a-infected patients, lower response rates were 
observed in patients with IL28B  non-CC and cirrhosis 
- factors known to affect response to pegIFN/RBV. 
Consistent with these observations, a multivariate 
logistic regression analysis in GT1b-infected patients 
demonstrated that SVR12 was associated with 
IL28B  host genotype (CC vs  non-CC, P  = 0.011) and 
cirrhosis status (absent vs  present, P  = 0.031). NS5A 
polymorphisms associated with daclatasvir resistance 
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(at L28, R30, L31, or Y93) were observed in 17.3% of 
GT1b-infected patients at baseline; such variants did 
not appear to be absolute predictors of failure since 
72.1% of these patients achieved SVR12 compared 
with 86.9% without these polymorphisms. Among 
GT1b-infected patients, treatment was completed by 
85.4% (229/268) in the daclatasvir group, and by 
85.1% (114/134) in the telaprevir group, and among 
GT1a-infected patients, by 67.2% (90/134) and 69.7% 
(46/66), respectively. Discontinuations (of all 3 agents) 
due to an AE were more frequent with telaprevir than 
with daclatasvir, whereas discontinuations due to lack 
of efficacy were more frequent with daclatasvir, due, in 
part, to differences in futility criteria. 
CONCLUSION: Daclatasvir plus pegIFN/RBV demons-
trated noninferiority to telaprevir plus pegIFN/RBV for 
SVR12 and was well-tolerated in treatment-naive GT1b-
infected patients, supporting the use of daclatasvir with 
other direct-acting antivirals. 
Key words: Direct-acting antiviral; Chronic hepatitis C; 
Daclatasvir; Genotype 1b; NS5A inhibitor; Liver disease 
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This phase 3 study describes the first 
prospective comparison of an NS5A inhibitor and an 
NS3/4A protease inhibitor in peginterferon-based 
regimens. Combinations of peginterferon alfa-2a/
ribavirin (pegIFN/RBV) with boceprevir or telaprevir 
were the standard-of-care for genotype (GT) 1-infected 
patients at the time of study design. In treatment-naive 
GT1b-infected patients, daclatasvir (NS5A inhibitor) plus 
pegIFN/RBV achieved a sustained virologic response 
at posttreatment week 12 (SVR12) of 85% and 
demonstrated noninferiority to telaprevir plus pegIFN/
RBV showing 81% SVR12. Daclatasvir plus pegIFN/RBV 
was well-tolerated, with a superior safety profile for 
anemia compared with telaprevir plus pegIFN/RBV. 
These results support the ongoing investigation of 
daclatasvir in all-oral combinations in multiple patient 
populations. 
Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-
Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, 
Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, 
Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener 
T, Hughes EA, Yin PD, Noviello S. Daclatasvir vs telaprevir 
plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. 




Chronic infection with hepatitis C virus (HCV) affects 
130-150 million people globally and is a major cause of 
cirrhosis and hepatocellular carcinoma[1]. Of the 7 HCV 
genotypes (GTs) identified[2], GT1 is the most prevalent 
worldwide, and accounts for 75% of all infections in 
the United States (US)[3]. GT1 can be classified into 
the two main subtypes GT1a and GT1b, of which GT1b 
is the most common worldwide, predominating in 
Europe, Japan, and China; in the US 36% of all GT1 
infections are subtype 1b[4].
Peginterferon alfa plus ribavirin (pegIFN/RBV) 
has traditionally been used to treat HCV. However, 
this regimen achieves only limited sustained virologic 
response (SVR) rates of 40%-50%[5,6] and is associated 
with a high frequency of adverse events (AEs)[7]. 
Although pegIFN/RBV-based therapies continue to 
be the standard of care in some countries[8], HCV 
treatment has evolved toward direct-acting antiviral 
agents (DAAs) that target specific viral proteins[5,6], 
with the first all-oral combinations for GT1 recently 
approved in Japan, Europe, the US, and Canada[9-15]. 
Combinations of pegIFN/RBV with one of the 
NS3/4A protease inhibitors boceprevir or telaprevir 
were the first DAA-based regimens approved and at 
the time of study design, the standard-of-care for 
GT1-infected patients. With telaprevir plus pegIFN/
RBV, SVR rates increased from < 50% with pegIFN/
RBV alone to 72%-75% in GT1-infected, treatment-
naive patients[16-18]. However, skin rash and anemia 
are frequent, and sometimes severe, adverse events 
(AEs) observed with telaprevir[16-19]. In patients 
treated with telaprevir plus pegIFN/RBV, rash has 
been reported in 35%-37% of patients (compared 
with 24% with pegIFN/RBV), necessitating premature 
discontinuation of telaprevir in 7% of patients, and 
anemia in 37%-42% (compared with 19% with 
pegIFN/RBV)[16-18]. Combinations of pegIFN/RBV 
with more recent DAAs, such as the NS5B inhibitor 
sofosbuvir or the NS3/4A protease inhibitor simeprevir, 
achieved SVR rates of 80%-90% and demonstrated 
a more favorable safety profile than telaprevir plus 
pegIFN/RBV[20-22]. Telaprevir plus pegIFN/RBV has 
been compared with simeprevir plus pegIFN/RBV 
in treatment-experienced GT1-infected patients[23]; 
however, for treatment-naive patients, no direct 
comparison of telaprevir vs a non-protease inhibitor 
DAA has been performed to date.
Daclatasvir is a potent, once-daily, pangenotypic 
NS5A inhibitor[24,25] that has been studied and shown 
to be well-tolerated in > 13000 patients. In phase 2 
trials in treatment-naive patients infected with GT1-4, 
daclatasvir + pegIFN/RBV demonstrated greater 
efficacy than pegIFN/RBV alone[26,27]. In GT1-infected 
patients, daclatasvir plus pegIFN/RBV achieved SVR 
at posttreatment week 24 (SVR24) rates of 60% 
compared with 38% with pegIFN/RBV; response rates 
were consistently higher in patients with GT1b (77%) 
than in those with GT1a (55%)[27], a finding that has 
also been observed with other DAA + pegIFN/RBV 
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at week 2 of therapy]; (2) week 12 HCV-RNA > 
1000 IU/mL; or (3) week 24 HCV-RNA ≥ LLOQ. In 
the telaprevir group, treatment futility was defined 
per prescribing information as week 4 or 12 HCV-
RNA > 1000 IU/mL or week 24 HCV-RNA detectable 
confirmed; virologic breakthrough was not included 
in the telaprevir futility criteria, per the prescribing 
information[19]. Relapse was defined as undetectable 
HCV-RNA at the end of treatment (EOT) followed by 
confirmed HCV-RNA ≥ LLOQ at any follow-up visit. 
Patients
The study included treatment-naive patients aged 18 
years or older, with GT1a or GT1b infection, and HCV-
RNA ≥ 10000 IU/mL at screening. Patients with no 
cirrhosis or compensated cirrhosis [by liver biopsy at 
any time, or by FibroScan™ (≥ 14.6 kPa) within 1 year 
of screening] were eligible for inclusion. No previous 
treatment of HCV with interferon-based regimens or 
DAAs was allowed. Other exclusion criteria included 
evidence of decompensated liver disease (including 
a history or presence of ascites, bleeding varices, 
or hepatic encephalopathy), evidence of a medical 
condition contributing to chronic liver disease other 
than HCV, documented or suspected hepatocellular 
carcinoma or other malignancies, co-infection with 
HIV or hepatitis B virus, alanine aminotransferase ≥ 
5 × the upper limit of normal, hemoglobin < 12 g/dL 
(120 g/L) for women and < 13 g/dL (130 g/L) for 
men, platelet count < 90 × 109 cells/L, international 
normalized ratio ≥ 1.7, albumin < 3.5 g/dL (35 g/L), 
or any criterion that would exclude the patient from 
receiving pegIFN/RBV or telaprevir. Patients were 
randomized to a regimen within stratum via block 
randomization (block size of 6) and using an interactive 
voice response system prepared by the sponsor.
Objectives and assessments
Primary and secondary objectives were amended 
during enrollment to focus on GT1b-infected patients 
based on the results of previous phase 2 data[27]. The 
primary objective was to demonstrate that daclatasvir 
plus pegIFN/RBV was noninferior to telaprevir plus 
pegIFN/RBV for SVR at posttreatment week 12 (HCV-
RNA < LLOQ at posttreatment week 12) in GT1b-
infected patients. The first two secondary objectives 
were to demonstrate that the rates of anemia 
(hemoglobin < 10 g/dL) and of rash-related events, 
through week 12, were lower with daclatasvir plus 
pegIFN/RBV than with telaprevir plus pegIFN/RBV, 
among GT1b-infected patients (see Supplementary 
Material and Methods for the definition of rash-
related events). Additional secondary objectives 
included noninferiority comparisons between arms 
of undetectable HCV-RNA at week 4 [rapid virologic 
response (RVR)], week 12 [complete early virologic 
response (cEVR)], and weeks 4 and 12 (eRVR), and 
HCV-RNA < LLOQ at post-treatment week 24 (SVR24), 
combinations[16,21,28]. Daclatasvir-containing pegIFN-
free regimens are approved for treatment of chronic 
HCV infection in a number of countries: daclatasvir 
plus asunaprevir (ASV, NS3 inhibitor) was approved 
as the first all-oral treatment for GT1 in Japan[9], and 
daclatasvir plus sofosbuvir (with or without ribavirin) 
is approved in Europe for GT1, 3, and 4[10], and 
in Canada for GT1, 2, and 3[29]. Daclatasvir is also 
approved in the US, indicated in combination with 
sofosbuvir for the treatment of chronic HCV GT3 
infection[30].
This phase 3 COMMAND-3 study compared the 
safety and efficacy of daclatasvir, an NS5A inhibitor, 
with that of telaprevir, a protease inhibitor, each in 
combination with pegIFN/RBV, in treatment-naive 




This was a phase 3, randomized, open-label, non-
inferiority study in treatment-naive patients with GT1 
infection (Study AI444-052; ClinicalTrials.gov number 
NCT01492426). Overall, 602 patients were randomly 
assigned (2:1) to daclatasvir vs telaprevir, stratified 
by IL28B rs12979860 host genotype (CC vs non-
CC), cirrhosis status (compensated cirrhosis vs no 
cirrhosis), and HCV GT1 subtype (GT1a vs GT1b). 
Patients with compensated cirrhosis were capped at 
25%. GT1a-infected patients were capped at 200 
(33%); this cap was introduced during enrollment 
(May 2012) based on data from a previous daclatasvir 
phase 2 study indicating that daclatasvir was more 
effective in GT1b-infected than in GT1a-infected 
patients[27]. Patients were treated with daclatasvir 60 
mg/d (n = 402) or telaprevir 750 mg 3 times/d (n = 
200) in combination with pegIFN alfa-2a 180 µg once 
weekly and RBV [weight-based dosing of 1000 mg/d (< 
75 kg) or 1200 mg/d (≥ 75 kg)]. Daclatasvir-treated 
patients with undetectable HCV-RNA at weeks 4 and 
12 [extended rapid virologic response (eRVR)] had 
a planned treatment duration of 24 wk of daclatasvir 
plus pegIFN/RBV; those without eRVR received an 
additional 24 wk of pegIFN/RBV (total of 48 wk of 
therapy), provided they did not experience treatment 
futility. Telaprevir-treated patients received 12 wk 
of telaprevir plus pegIFN/RBV, followed by 12 (with 
eRVR) or 36 (without eRVR) weeks of pegIFN/RBV 
alone, provided they did not experience treatment 
futility. Patients in both groups were followed for 24 wk 
(without eRVR) or 48 wk (with eRVR) posttreatment.
In the daclatasvir group, treatment futility, which 
mandated discontinuation of all study drugs, was 
defined as: (1) virologic breakthrough [> 1-log10 
increase in HCV-RNA over nadir or confirmed HCV-RNA 
≥ lower limit of quantification (LLOQ) after confirmed 
undetectable HCV-RNA while on treatment beginning 
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in GT1b-infected patients. The final secondary 
objective was a noninferiority comparison between 
arms of SVR12 in GT1a-infected patients.
HCV-RNA was assayed using the Roche HCV 
COBAS® TaqMan® test v2.0 (LLOQ = 25 IU/mL; limit 
of detection approximately 10 IU/mL). HCV GT and 
subtype were determined by Versant HCV GT 2.0 
assay (LIPA) and were analyzed by ICON Central 
Laboratories, Inc. IL28B genotype was determined by 
polymerase chain reaction amplification coupled with 
allelic discrimination. Resistance testing was performed 
using population-based sequencing of the NS5A 
region for all patients at baseline, and for patients 
with virologic failure or relapse and with amplifiable 
(HCV-RNA ≥ 1000 IU/mL) plasma samples. Safety 
monitoring was based on the incidences of AEs, serious 
AEs (SAEs), discontinuations due to AEs, laboratory 
abnormalities, vital signs, and physical examinations.
Statistical analysis
The statistical methods of this study were reviewed 
by the biometrics group at Bristol-Myers Squibb. A 
noninferiority margin of -12% was employed in this 
study. A 2-sided 95% confidence interval (CI) for 
the difference in rates, daclatasvir plus pegIFN/RBV 
minus telaprevir plus pegIFN/RBV, was used to test 
for noninferiority. To demonstrate noninferiority, the 
lower bound of the CI had to be > -0.12. A sample 
size of 400 GT1b-infected patients, randomized 2:1 to 
daclatasvir plus pegIFN/RBV vs telaprevir plus pegIFN/
RBV, provided 91% power to show that the SVR12 
rate of daclatasvir plus pegIFN/RBV was noninferior 
to that of telaprevir plus pegIFN/RBV at the 5% 
significance level, assuming SVR12 rates of 85% for 
both regimens[16].
Each secondary comparison was conducted at 
the 5% level and proceeded hierarchically according 
to the order of the objectives (see Objectives and 
assessments). Testing of an endpoint was performed 
only if the null hypothesis of the preceding endpoint 
was rejected. Safety comparisons, for anemia and 
rash-related events, were for superiority, i.e., to 
show that daclatasvir plus pegIFN/RBV was less toxic 
than telaprevir plus pegIFN/RBV. Secondary efficacy 
comparisons were for noninferiority (noninferiority 
margin -12%). 
Efficacy analyses were restricted to all treated 
patients and were performed using a modified intent-
to-treat (mITT) analysis (patients with missing HCV-
RNA measurements were considered failures). For 
the primary endpoint, an analysis based on SVR 
documented on or after (if follow-up week 12 HCV-
RNA was missing) posttreatment week 12 was also 
conducted. A stratum-adjusted, 2-sided, asymptotic 
95%CI was used to compute the difference in SVR12 
rates between arms[31]. The strata were those used 
in the randomization. Stratum-adjusted CIs were 
also used for testing differences between rates for 
secondary efficacy endpoints. 
All authors had access to the study data and have 
reviewed and approved the final manuscript.
RESULTS
Patient disposition
Overall, 793 patients were screened; of these, 402 
GT1b-infected patients were randomized and treated 
with daclatasvir plus pegIFN/RBV (n = 268) or 
telaprevir plus pegIFN/RBV (n = 134), and 200 GT1a-
infected patients were randomized and treated with 
daclatasvir plus pegIFN/RBV (n = 134) or telaprevir 
plus pegIFN/RBV (n = 66) (Figure 1). Among GT1b-
infected patients, treatment was completed by 
85.4% (229/268) in the daclatasvir group, and by 
85.1% (114/134) in the telaprevir group, and among 
GT1a-infected patients, by 67.2% (90/134) and 
69.7% (46/66), respectively. Discontinuations (of 
all three agents) due to an AE were more frequent 
with telaprevir than with daclatasvir, whereas dis-
continuations due to lack of efficacy were more 
frequent with daclatasvir. This was due, in part, to the 
different futility criteria in the two treatment groups. 
Posttreatment follow-up was initiated by 384 patients 
in the daclatasvir group and by 191 patients in the 
telaprevir group and was completed by 359 (93.5%) 
and 181 (94.8%), respectively. 
Baseline characteristics 
Patient demographics and disease characteristics were 
generally balanced across treatment arms (Table 1); 
however, there was a higher proportion of black/African 
Americans in the daclatasvir groups (6.0%-8.2%) than 
in the telaprevir groups (2.2%-3.0%). Mean HCV-RNA 
levels ranged from 6.23-6.31 log10 IU/mL, 9.7%-13.6% 
of patients had cirrhosis, and there was a high 
proportion of patients with a non-CC IL28B genotype 
(68.7%-79.9%) across all groups. 
Efficacy in GT1b-infected patients
In GT1b-infected patients, SVR12 rates were 85.1% 
(228/268) with daclatasvir plus pegIFN/RBV vs 
81.3% (109/134) with telaprevir plus pegIFN/RBV 
(mITT; primary endpoint) (Table 2); the difference 
between treatment arms was 4.3% (95%CI: -3.3% 
to 11.9%), demonstrating noninferiority (lower bound 
of the 95%CI greater than -12%). Similar SVR12 
rates in GT1b-infected patients were obtained when 
using the next available HCV-RNA value for patients 
with missing posttreatment week 12 measurements 
[daclatasvir plus pegIFN/RBV: 85.8% (230/268); 
telaprevir plus pegIFN/RBV: 82.1% (110/134)]. 
Response rates observed for the secondary efficacy 
endpoints (RVR, eRVR, cEVR, SVR24) in GT1b-infected 
patients appeared similar between treatment arms 
(Table 2); however, no formal comparisons could 
be made because the test for the difference in rash-
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related events between arms, which preceded the 
comparisons of secondary efficacy endpoints in the 
testing hierarchy, was not statistically significant (see 
Safety section). Among GT1b-infected patients with 
SVR12, three patients did not achieve SVR24 (one 
patient in each arm relapsed between posttreatment 
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Figure 1  Patient disposition. Efficacy analyses were based on a modified intent-to-treat analysis (included all randomized and treated patients who had received 
≥ 1 dose of study medication; patients with missing HCV RNA measurements were considered failures). 1No longer met study entry criteria during the screening 
period (n = 139), withdrew consent (n = 28), administrative reason by sponsor (n = 5), lost to follow-up (n = 3), pretreatment AE (n = 2), or other reasons (n = 11); 
2All 3 study drugs discontinued; 3Lack of efficacy (n = 15; 11 virologic breakthroughs, 3 futility, and 1 other), AE (n = 14), patient request (n = 6), lost to follow-up (n = 
3), and withdrew consent (n = 1); 4AE (n = 17), withdrew consent (n = 2), and lost to follow-up (n = 1); 5Lack of efficacy (n = 23; 11 virologic breakthroughs, 4 futility, 
8 other), adverse event (n = 11), lost to follow-up (n = 6), patient request (n = 1), and other (n = 3); 6Lack of efficacy (n = 5; 3 futility, 2 other), AE (n = 8), patient 
request (n = 3), lost to follow-up (n = 3), and death (n = 1; the death occurred in a patient who had discontinued treatment at week 16 due to bacteremia and died at 
posttreatment week 4 due to sepsis secondary to HCV-related cirrhosis). DCV: Daclatasvir; GT: Genotype; SVR12: Sustained virologic response (HCV-RNA < LLOQ) 
at posttreatment week 12; TVR: Telaprevir.
Table 1  Patient demographics and baseline disease characteristics
 GT1b GT1a
n  (%) DCV + pegIFN/RBV 
(n  = 268)
TVR + pegIFN/RBV 
(n  = 134)
DCV + pegIFN/RBV 
(n  = 134)
TVR + pegIFN/RBV 
(n  = 66)
Age (yr), median (range) 46.0 (18-71) 48.0 (19-69) 49.0 (19-67)  51.5 (28-69)
Male 159 (59.3) 72 (53.7) 98 (73.1)  47 (71.2)
Race
   White 243 (90.7) 129 (96.3) 120 (89.6)  63 (95.5)
   Black/African American 16 (6.0)   3 (2.2) 11 (8.2)  2 (3.0)
   Asian   6 (2.2)   2 (1.5)   1 (0.7) 0
   Other   3 (1.1) 0   2 (1.5)  1 (1.5)
HCV-RNA log10 (IU/mL), mean (SD)  6.23 (0.701) 6.23 (0.577)  6.30 (0.637) 6.31 (0.636)
HCV-RNA ≥ 800000 IU/mL 196 (73.1)  97 (72.4)  104 (77.6)  51 (77.3)
IL28B genotype
   CC   53 (19.8) 27 (20.1)  42 (31.3) 20 (30.3)
   CT 161 (60.1) 86 (64.2)  73 (54.5) 37 (56.1)
   TT   53 (19.8) 21 (15.7)  19 (14.2)   9 (13.6)
   Not reported   1 (0.4) 0 0 0
Cirrhosis
   Present 26 (9.7) 15 (11.2)  16 (11.9) 9 (13.6)
DCV: Daclatasvir; GT: Genotype; HCV: Hepatitis C virus; pegIFN: Peginterferon alfa-2a; RBV: Ribavirin; TVR: Telaprevir.
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weeks 12 and 24, and one patient in the daclatasvir 
group had a missing posttreatment week 24 HCV-RNA 
measurement).
In GT1b-infected patients, observed SVR12 rates 
tended to be higher in the daclatasvir arm than in the 
telaprevir arm in subgroups based on demographic 
and disease status, such as age, sex, IL28B, cirrhosis, 
and baseline HCV-RNA level (Table 3). Of note, among 
cirrhotics, a higher proportion of patients receiving 
daclatasvir vs telaprevir achieved SVR12 (76.9% vs 
66.7%). In the daclatasvir group, SVR12 appeared 
to be independent of age and sex. In both treatment 
groups, lower response rates were observed in 
patients with IL28B non-CC, baseline HCV-RNA ≥ 
800000 IU/mL, or cirrhosis, baseline factors known 
to affect response to pegIFN/RBV[32]. Consistent with 
these observations, a multivariate logistic regression 
analysis in GT1b-infected patients demonstrated that 
SVR12 was associated with IL28B host genotype (CC 
vs non-CC, P = 0.011), baseline HCV-RNA (< 800000 
IU/mL vs ≥ 800000 IU/mL, P = 0.016), and cirrhosis 
status (absent vs present, P = 0.031). Virologic 
response was not associated with age, sex, race, or 
type of treatment (Supplementary Table 3). 
Virologic failure in GT1b-infected patients
Forty (14.9%) patients in the daclatasvir group and 
25 (18.7%) patients in the telaprevir group did not 
achieve SVR12 (Table 2). Virologic breakthrough 
occurred in 11 (4.1%) patients in the daclatasvir 
group. Virologic breakthrough was not assessed as 
a futility criteria for the telaprevir group, per the 
telaprevir prescribing information[19]. Relapse (among 
patients with undetectable HCV-RNA at EOT) was 
reported in 12/244 (4.9%) patients in the daclatasvir 
group and 20/131 (15.3%) patients in the telaprevir 
group. Other posttreatment failures, occurring in 
3424 March 28, 2016|Volume 22|Issue 12|WJG|www.wjgnet.com
Table 2  Efficacy endpoints and failures in GT1b-infected patients
Outcome, n/n  (%) DCV + pegIFN/RBV TVR + pegIFN/RBV
Efficacy
   SVR12 (mITT)1,2 228/268 (85.1) 109/134 (81.3)
   SVR12 on or after PT week 123 230/268 (85.8) 110/134 (82.1)
   RVR (HCV-RNA undetectable at week 4)1,4 207/268 (77.2) 106/134 (79.1)
   cEVR (HCV-RNA undetectable at week 12)1,4 243/268 (90.7) 121/134 (90.3)
   eRVR (HCV-RNA undetectable at weeks 4 and 12)1,4 201/268 (75.0)   98/134 (73.1)
   EOTR (HCV-RNA undetectable at EOT) 244/268 (91.0) 131/134 (97.8)
   SVR241,4 226/268 (84.3) 108/134 (80.6)
Failures
   Non-SVR12   40/268 (14.9) 25/134 (18.7)
   On-treatment failures 21/268 (7.8) 3/134 (2.2)
      Virologic breakthrough 11/268 (4.1) NA5
      Treatment futility other than virologic breakthrough   3/268 (1.1) 0
      HCV-RNA detectable at EOT   7/268 (2.6) 3/134 (2.2)
Posttreatment relapse6 12/244 (4.9) 20/131 (15.3)
HCV-RNA undetectable at EOT but missing PT week 12 data   7/244 (2.9) 2/131 (1.5)
1Patients with missing data at posttreatment week 12 were considered failures; 2Difference, 4.3%; 95%CI: -3.3% to 11.9%; noninferior at the 5% significance 
level (lower bound of the 95%CI was > -12%); 3Patients with missing data at posttreatment week 12 were considered responders if the next available 
HCV-RNA value was < LLOQ; 4Differences and 95%CIs were as follows: RVR, -1.5% (-9.8% to 6.8%); cEVR, 0.6 (-5.5% to 6.6%); eRVR, 2.2% (-6.8% to 
11.2%); SVR24, 4.4% (-3.5% to 12.2%); 5Not included in TVR futility criteria per prescribing information; 6Assessed in patients with undetectable HCV-
RNA at EOT. cEVR: Complete early virologic response; DCV: Daclatasvir; EOT: End of treatment; EOTR: End of treatment response; eRVR: Early rapid 
virologic response; GT: Genotype; HCV: Hepatitis C virus; LLOQ: Lower limit of quantitation; mITT: Modified intent-to-treat; NA: Not applicable; pegIFN: 
Peginterferon alfa-2a; PT: Posttreatment; RBV: Ribavirin; SVR12: Sustained virologic response (HCV-RNA < LLOQ) at posttreatment week 12; RVR: Rapid 
virologic response; SVR24: Sustained virologic response at posttreatment week 24; TVR: Telaprevir.
Table 3  Proportion of GT1b-infected patients with SVR12 
by subgroups
SVR121, n/n  (%) DCV + pegIFN/RBV
(n  = 268)
TVR + pegIFN/RBV 
(n  = 134)
Age (yr)
   < 65 218/256 (85.2) 103/126 (81.7)
   ≥ 65     10/12 (83.3)         6/8 (75.0)
Sex
   Male 134/159 (84.3)     61/72 (84.7)
   Female   94/109 (86.2)     48/62 (77.4)
Race
   White 208/243 (85.6) 105/129 (81.4)
   Black/African American     11/16 (68.8)         2/3 (66.7)
   Asian           6/6 (100.0)           2/2 (100.0)
   Other           3/3 (100.0) 0
Baseline HCV-RNA
   < 800000 IU/mL     66/72 (91.7)     33/37 (89.2)
   ≥ 800000 IU/mL 162/196 (82.7)     76/97 (78.4)
Cirrhosis
   Absent 208/242 (86.0)   99/119 (83.2)
   Present     20/26 (76.9)     10/15 (66.7)
IL28B genotype 
   CC     51/53 (96.2)     23/27 (85.2)
   CT 132/161 (82.0)     69/86 (80.2)
   TT     44/53 (83.0)     17/21 (81.0)
1mITT analysis (patients with missing data at posttreatment week 12 were 
considered failures). DCV: Daclatasvir; GT: Genotype; HCV: Hepatitis C 
virus; pegIFN: Peginterferon alfa-2a; RBV: Ribavirin; SVR12: Sustained 
virologic response (HCV-RNA < LLOQ) at posttreatment week 12; TVR: 
Telaprevir.
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7/244 (2.9%) patients in the daclatasvir group and 
2/131 (1.5%) patients in the telaprevir group, were 
due to undetectable HCV-RNA at EOT but missing 
posttreatment week 12 HCV-RNA. 
At baseline, 249/268 GT1b-infected patients 
treated with daclatasvir plus pegIFN/RBV had available 
NS5A population-based sequencing data. In 43/249 
(17.3%) of these patients, one or more of the NS5A 
polymorphisms L28M/V, R30H/Q, L31M, or Y93H were 
detected at baseline; of these, 72.1% (31 patients) 
achieved SVR12, of which 61.3% (19 patients) had 
a non-CC IL28B genotype. Of the remaining 12 
patients who did not achieve SVR12, 11 had a non-
CC IL28B genotype. Among patients without NS5A 
polymorphisms at baseline, 87% (179/206) achieved 
SVR12.
Among the 40 GT-1b patients in the daclatasvir 
group who did not achieve SVR12, 32 had evaluable 
samples at baseline and at the time of failure. In 
two patients, the same NS5A resistance-associated 
variants (RAVs) were detected at both baseline and 
failure: L31M-Y93H in one patient, and L28V-R30Q-
L31M-Q62D in a second patient. Among the remaining 
30 patients, the most common treatment-emergent 
NS5A RAVs were L31F/I/M/V (22 patients) and 
Y93H (21 patients); RAVs at L31 and Y93 emerged 
together in 18 patients. NS5A L31 and Y93 RAVs also 
emerged together in one daclatasvir-treated patient 
who achieved SVR12 but relapsed at posttreatment 
week 24. Of the eight non-SVR12 patients who 
were not tested at failure [due to undetectable HCV-
RNA at last available visit (n = 5), missing HCV-RNA 
measurement (n = 2), or lost to follow-up while HCV-
RNA was < 1000 IU/mL (n = 1)], seven had no NS5A 
polymorphisms at baseline, and one had no baseline 
NS5A sequence available.
Efficacy outcomes in GT1a-infected patients
In GT1a-infected patients, SVR12 rates were 64.9% 
in the daclatasvir group and 69.7% in the telaprevir 
group. Other outcomes and treatment failures in 
GT1a-infected patients are shown in Supplementary 
Table 1. Baseline NS5A sequences were available for 
123 GT1a-infected patients treated with daclatasvir; 
the polymorphisms Q30R, L31M, and/or Y93N were 
detected in 6 (5%) patients, of whom 5 achieved 
SVR12. Among 34 GT1a-infected virologic failures 
with evaluable samples, the most common emergent 
NS5A RAVs at failure were Q30E/H/R (32 patients). 
In patients with emergent Q30 RAVs, L31 variants 
were also frequently detected, either as on-treatment 
emergent RAVs (19 patients) or pre-existing at 
baseline (one patient). In a daclatasvir-treated patient 
who relapsed after achieving SVR12, the NS5A RAV 
Q30E was detected at posttreatment week 24.
Safety
Safety, pooled across GT1 subtypes, is shown in 
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Table 4  Overall on-treatment safety in GT1-infected patients
Event, n  (%) DCV + pegIFN/RBV (n  = 402) TVR + pegIFN/RBV (n  = 200)1
Death    1 (0.2)2  1 (0.5)2
SAEs  26 (6.5)2  20 (10.0)2
AEs leading to discontinuation of any study drug  28 (7.0)2  37 (18.5)2
AEs leading to discontinuation of all 3 study drugs 25 (6.2) 25 (12.5)
AEs (grade 1-4) ≥ 20%
   Fatigue 140 (34.8) 81 (40.5)
   Headache 137 (34.1) 57 (28.5)
   Asthenia 109 (27.1) 53 (26.5)
   Pruritus 107 (26.6) 75 (37.5)
   Anemia   96 (23.9) 99 (49.5)
   Rash   93 (23.1) 69 (34.5)
   Nausea   88 (21.9) 74 (37.0)
   Neutropenia   87 (21.6) 27 (13.5)
   Alopecia   86 (21.4) 32 (16.0)
   Influenza-like illness   85 (21.1) 38 (19.0)
   Dry skin   84 (20.9) 34 (17.0)
   Pyrexia   80 (19.9) 42 (21.0)
Grade 3 or 4 emergent laboratory abnormalities
   Hemoglobin 26 (6.5) 41 (20.5)
   Absolute neutrophil count 104 (25.9) 41 (20.5)
   Lymphocytes   67 (16.7) 44 (22.0)
   Platelet count 15 (3.7) 8 (4.0)
   ALT   3 (0.7) 4 (2.0)
   AST   7 (1.7) 1 (0.5)
   Total bilirubin   4 (1.0) 6 (3.0)
   Serum creatinine increased   1 (0.2) 0
1n = 198 for grade 3/4 laboratory abnormalities; 2Further information provided in supplementary material. AE: Adverse event; ALT: Alanine 
aminotransferase; AST: Aspartate aminotransferase; DCV: Daclatasvir; GT: Genotype; pegIFN: Peginterferon alfa-2a; RBV: Ribavirin; SAE: Serious adverse 
event; TVR: Telaprevir. 
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Table 4. AEs leading to discontinuation of any study 
drug were more frequent with telaprevir (18.5%) 
vs daclatasvir (7.0%). In the daclatasvir group, the 
most common (≥ 1%) AEs leading to discontinuation 
of any study drug were psychiatric (1.5%), skin 
(1.5%), or hemolytic events (1.2%); in the telaprevir 
group the most common AEs were skin events 
(9.0%), hemolytic events (4.5%), general disorders 
(3.0%), gastrointestinal events (2.0%), psychiatric 
events (1.5%), infections and infestations (1.5%), 
nervous system disorders (1.5%), or renal events 
(1.0%). Serious AEs (SAEs) were reported in 6.5% of 
daclatasvir-treated patients and in 10.0% of telaprevir-
treated patients. Drug-related SAEs were reported in 
3.5% (n = 14) and 8.0% (n = 16) of treated patients 
in the daclatasvir and telaprevir arms, respectively, 
including one case of drug reaction with eosinophilia 
and systemic symptoms (DRESS) syndrome in each 
treatment group and five cases of anemia in the 
telaprevir group. The daclatasvir-treated patient with 
DRESS syndrome, a 62-year-old male with GT1b-
infection, developed grade 3 rash after approximately 
2.5 mo of therapy, followed by hyperthermia and 
hypereosinophilia (eosinophils 1.12 × 109 cells/L) 
leading to hospitalization. Topical corticosteroid 
(betamethasone) and trimeprazine resulted in rapid 
improvement and normalization of the eosinophil 
count (0.41 × 109 cells/L) within 10 d of discontinuing 
study therapy. The patient achieved SVR12. The 
five telaprevir-treated patients with a related SAE of 
anemia all had grade 4 anemia with hemoglobin levels 
of 54-72 g/L; all 5 patients received blood transfusions 
and 2 discontinued study therapy. The most common 
(> 25%) AEs were fatigue, headache, asthenia, and 
pruritus in the daclatasvir group, and anemia, fatigue, 
nausea, rash, pruritus, headache, and asthenia in the 
telaprevir group. Grade 3 or 4 laboratory abnormalities 
were comparable between treatment groups, except 
for grade 3 or 4 hemoglobin levels, which were more 
frequent with telaprevir (20.5%) than with daclatasvir 
(6.5%). Grade 3 or 4 bilirubin elevations occurred in 3% 
of patients in the telaprevir group compared with 1% 
in the daclatasvir group. 
One death was reported in each treatment group, 
both of which occurred during off-treatment follow-
up and were considered unrelated to therapy. In the 
daclatasvir group, the patient died during posttreat-
ment week 4 from multiple fractures and a subdural 
hematoma related to a fall. In the telaprevir group, the 
patient, who had discontinued treatment at week 16 
(due to bacteremia), died during posttreatment week 
4 from sepsis secondary to cirrhosis due to hepatitis C.
Grade 1-4 anemia was experienced by 23.9% 
of GT1-infected patients in the daclatasvir group, 
and 49.5% in the telaprevir group, including 3.2% 
(n = 13) and 13.5% (n = 27), respectively, with 
grade 3 or 4 anemia. Incidences for the secondary 
endpoint of hemoglobin < 10 g/dL in GT1b-infected 
patients through week 12 were significantly lower 
in the daclatasvir group than in the telaprevir group 
(daclatasvir: 18.3% vs telaprevir: 47.4%; difference, 
-29.1; 95%CI: -38.8% to -19.4%; Figure 2). Grade 
1-4 rash [single Medical Dictionary for Regulatory 
Activities (MedDRA) term] was reported in 23.1% of 
GT1-infected patients in the daclatasvir group and in 
34.5% in the telaprevir group, including 1.0% (n = 
4) and 3.5% (n = 7), respectively, with grade 3 or 4 
rash. Incidences for the secondary endpoint of rash-
related events (composite MedDRA term) in GT1b-
infected patients through week 12 were also lower 
with daclatasvir than with telaprevir, however the 
difference was not statistically significant given the 
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Figure 2  Safety secondary endpoints in GT1b-infected patients (first 12 wk). mITT analysis (patients with missing data at posttreatment week 12 were considered 
failures). 1Superior at the 5% significance level; upper bound of the 95%CI was 0%; 2One patient in the TVR arm had no measurement due to discontinuation prior to 
on-treatment laboratory assessment; 3Includes rash-related SAEs, AEs leading to discontinuation, and grade 3 or 4 AEs. AE: Adverse event; CI: Confidence interval; 
DCV: Daclatasvir; GT: Genotype; Hgb: Hemoglobin; pegIFN: Peginterferon alfa-2a; RBV: Ribavirin; SAE: Serious adverse event; TVR: Telaprevir. 
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low event rates in both arms (daclatasvir: 1.9%; 
telaprevir: 5.2%; difference, -3.4; 95%CI: -7.5% to 
0.7%; Figure 2).
Safety was also assessed in subgroups of patients 
with and without cirrhosis at baseline (Supplementary 
Table 2). In both treatment arms, anemia, reduced 
platelet count, and elevated total bilirubin were 
more frequent in patients with than in those without 
cirrhosis. Among cirrhotic patients, those treated with 
telaprevir experienced a higher frequency of the AEs 
anemia (58.3% vs 33.3%), rash (41.7% vs 21.4%), 
fatigue (50.0% vs 38.1%), and nausea (37.5% vs 
11.9%), and of SAEs (16.7% vs 7.1%); in contrast, 
neutropenia was more common with daclatasvir 
(26.2%) than with telaprevir (16.7%) but was not 
associated with an increase in infections (daclatasvir: 
21.4%; telaprevir: 41.7%). 
DISCUSSION
This study evaluated the efficacy and safety of 
daclatasvir plus pegIFN/RBV compared with telaprevir 
plus pegIFN/RBV in HCV GT1-infected patients and 
is the first head-to-head comparison of two different 
DAA classes - an NS5A inhibitor vs an NS3/4A 
protease inhibitor - in combination with pegIFN/RBV 
in treatment-naive patients. In treatment-experienced 
GT1-infected patients simeprevir (NS3/4A protease 
inhibitor) plus pegIFN/RBV has been compared with 
telaprevir plus pegIFN/RBV, with simeprevir plus 
pegIFN/RBV demonstrating noninferiority to telaprevir 
plus pegIFN/RBV for SVR12 (54% vs 55%) and a 
more favourable safety profile[23]. 
In the present study in treatment-naive, GT1b-
infected patients, SVR12 rates achieved with daclatasvir 
plus pegIFN/RBV were noninferior to those observed 
with telaprevir plus pegIFN/RBV, and anemia was 
significantly less frequent among daclatasvir-treated 
patients than in telaprevir-treated patients. Rash-
related events were also less common among patients 
receiving daclatasvir vs telaprevir. Daclatasvir plus 
pegIFN/RBV demonstrated high SVR12 rates in GT1b-
infected patients across all subgroups of baseline 
factors known to affect response rates to pegIFN/RBV 
(cirrhosis, IL28B genotype, age, sex, baseline viral 
load). Importantly, in difficult-to-cure patients with 
cirrhosis, SVR12 rates were higher with daclatasvir 
plus pegIFN/RBV than with telaprevir plus pegIFN/
RBV (76.9% vs 66.7%). On-treatment treatment 
futility was more common with daclatasvir than with 
telaprevir; however this may have been related to the 
different futility criteria between the two treatment 
groups. However, posttreatment relapse was more 
frequent with telaprevir than with daclatasvir (15% vs 
5%). 
Using population-based sequencing of the NS5A 
region, NS5A polymorphisms associated with daclatasvir 
resistance (L28, R30, L31, and/or Y93) were observed 
in 17% of GT1b-infected patients at baseline. Although 
such variants may be associated with virologic outcome 
to daclatasvir plus pegIFN/RBV, they do not appear to 
be absolute predictors of failure because 72% of GT1b-
infected patients with these polymorphisms at baseline 
achieved SVR12 in this study. Furthermore, since most 
(11/12) patients with baseline NS5A polymorphisms 
who did not achieve SVR12 also had a non-CC IL28B 
genotype, it may be that IL28B genotype has a stronger 
association with virologic failure. A similar observation 
was reported in a previous daclatasvir plus pegIFN/
RBV phase 2 study, in which only 2/10 GT1b-infected 
patients with L31 or Y93 variants failed to achieve a 
response, but 30/32 GT1b virologic failures were non-
CC IL28B[27]. 
A relevant consideration is that the persistence 
of RAVs may influence further treatment options in 
an IFN-free context. In this study, patients were not 
monitored beyond post-treatment week 24, thus 
analysis of the persistence of NS5A RAVs was not 
undertaken. However, persistence beyond one year 
has been described previously in GT1b- and GT1a-
infected patients[33,34]. Persistence of emergent NS5A 
RAVs has also been described from an interim analysis 
of a three-year follow-up study[35]. Detection of viral 
variants by direct sequencing limits the ability to 
detect low-frequency variants within a viral population; 
however, despite this limitation, the results of these 
analyses have been useful for describing relationships 
between RAVs and clinical outcomes. 
In this study, response rates with daclatasvir plus 
pegIFN/RBV were lower and virologic failure was more 
frequent in patients infected with HCV GT1a than in 
patients infected with GT1b. Most likely, this is due to a 
lower resistance barrier of daclatasvir in GT1a-infected 
patients rather than to a higher potency in GT1b-
infected patients, since the EC50 of daclatasvir was low 
in both GT1a-infected patients (20 pM) and GT1b-
infected patients (4 pM)[24]. These lower response rates 
observed among GT1a-infected patients are consistent 
with previous studies of daclatasvir[27] and have also 
been observed with other DAAs, including telaprevir[16], 
boceprevir[28], and simeprevir[21]. 
Daclatasvir plus pegIFN/RBV was generally well-
tolerated, with an overall safety profile similar to 
that of pegIFN/RBV alone, with no new safety or 
tolerability concerns attributable to daclatasvir. In 
the overall GT1-infected population, anemia events 
(grade 1-4 and grade 3 or 4) were less common in the 
daclatasvir group (24% and 3%, respectively) than 
in the telaprevir group (50% and 14%, respectively), 
and were also less frequently a reason for treatment 
discontinuation (daclatasvir: 0.5%; telaprevir: 4.0%). 
Among GT1b-infected patients, daclatasvir plus 
pegIFN/RBV demonstrated superiority over telaprevir 
plus pegIFN/RBV for the secondary endpoint of 
hemoglobin < 10 g/dL (18% vs 47%).
Grade 1-4 and grade 3 or 4 rash (single MedDRA 
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term) were also less frequent in the overall GT1-
infected population in patients receiving daclatasvir 
(23% and 1%, respectively) than in those receiving 
telaprevir (35% and 4%, respectively), as were 
discontinuations due to rash (daclatasvir: 0.2%; 
telaprevir: 4.5%). The grade 1-4 events of rash 
observed in the daclatasvir group are most likely 
related to pegIFN/RBV, because the observed rate 
(23%) is comparable to that historically reported with 
pegIFN/RBV alone[16,27], and no cases of rash have 
been reported with daclatasvir all-oral regimens, 
including daclatasvir plus sofosbuvir[36]. Rash-related 
events (composite MedDRA term) were evaluated as 
a secondary endpoint in this study in GT1b-infected 
patients, and a lower incidence was observed in those 
receiving daclatasvir than in those receiving telaprevir, 
but this difference was not statistically significant due 
to low event rates in both arms. The single case of 
DRESS syndrome observed with daclatasvir is the only 
case reported to date in the daclatasvir development 
program and real-word experience. 
At the time this study was designed, telaprevir 
plus pegIFN/RBV was the standard of care for the 
treatment of HCV GT1 infection; however, other 
DAAs have now been approved, both in combination 
with pegIFN/RBV and as part of IFN-free regimens. 
Currently approved all-oral treatment options for GT1-
infected patients include daclatasvir plus sofosbuvir 
± RBV (approved for GT1, 3, and 4 in the EU[10]), 
which has been shown to achieve SVR12 rates of up 
to 98% in treatment-naive GT1-infected patients[36], 
and the dual combination daclatasvir plus asunaprevir 
(approved for GT1b in Japan[9]), which has been shown 
to achieve SVR12 rates of 90% in GT1b-infected 
treatment-naive patients[37]. Other approved all-oral 
regimens include the combinations of sofosbuvir + 
ledipasvir ± RBV[11,12] and simeprevir plus sofosbuvir 
± RBV[13,14,38], which achieved SVR rates of up to 98% 
and 94%, respectively, in this patient population. 
Ombitasvir/paritaprevir/ritonavir plus dasabuvir, which 
was recently approved, provided SVR rates of 90% 
(without RBV) and 95%-97% (with RBV) in treatment-
naive noncirrhotic patients infected with GT1a, and 
of 99% (without RBV) and 98%-100% (with RBV) 
in those infected with GT1b[36,39,40]; in GT1-infected 
patients with cirrhosis SVR12 was 96%[41]. Daclatasvir 
is also being evaluated as part of an all-oral, fixed-dose 
combination with asunaprevir and beclabuvir (formerly 
BMS-791325). In phase 3 studies, this regimen without 
RBV has provided SVR12 rates of 92% in GT1a- 
and 1b-infected treatment-naive patients without 
cirrhosis[42], and SVR12 rates of 93%-98% in GT1a- 
and 1b-infected patients with compensated cirrhosis, 
with or without RBV[43]; in these studies, SVR12 rates 
were lower in patients infected with GT1a than in those 
infected with GT1b when RBV was excluded from the 
regimen.
Although all-oral regimens have become the new 
standard of care in chronic hepatitis C management, 
pegIFN/RBV-based therapies will remain a potentially 
important treatment option in such settings as low-
income countries or possibly for patients who have 
failed DAA-only therapies.
In conclusion, this first and only head-to-head 
comparison of two classes of DAAs in treatment-
naive patients demonstrates that daclatasvir plus 
pegIFN/RBV is noninferior to telaprevir plus pegIFN/
RBV for SVR12 for treatment of HCV GT1b infection. 
Daclatasvir plus pegIFN/RBV was generally well-
tolerated, with a significantly lower rate of anemia, 
and an observed lower rate of rash-related events 
compared with telaprevir plus pegIFN/RBV. The 
results of this study and other studies support the 
role of daclatasvir as an effective and well-tolerated 
component of interferon-free, all-oral HCV regimens 
across multiple genotypes.
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Background
Chronic infection with hepatitis C virus (HCV) affects 130-150 million people 
globally and is a major cause of cirrhosis and hepatocellular carcinoma. 
Peginterferon alfa plus ribavirin (pegIFN/RBV) has historically been used to 
treat HCV, although this regimen achieves only limited sustained virologic 
response (SVR) rates of 40%-50% in genotype 1 (GT1) infection. Whilst 
pegIFN/RBV-based therapies remain the standard of care in some countries, 
HCV treatment has evolved toward direct-acting antiviral agents (DAAs) that 
target specific viral proteins. 
Research frontiers
The combination of pegIFN/RBV with the NS3/4A protease inhibitor telaprevir 
was one of the first approved DAA-based regimens, and replaced pegIFN/RBV 
as the standard-of-care for GT1-infected patients. Skin rash and anemia are 
frequent, and at times severe, adverse events (AEs) observed with telaprevir. 
No direct comparison of telaprevir vs a non-protease inhibitor DAA has been 
performed to date. Daclatasvir is a potent, once-daily, pangenotypic NS5A 
inhibitor; this phase 3 study compared the safety and efficacy of daclatasvir 
with that of telaprevir, each in combination with pegIFN/RBV, in treatment-naive 
patients with GT1 infection, with a focus on GT1b-infected patients. 
Innovations and breakthroughs
Among GT1b-infected patients, daclatasvir plus pegIFN/RBV was noninferior 
to telaprevir plus pegIFN/RBV for SVR12 [85% (228/268) vs 81% (109/134); 
difference, 4.3% (95%CI: -3.3% to 11.9%)]. Daclatasvir was generally well-
tolerated: anemia (hemoglobin < 10 g/dL) was significantly less frequent with 
daclatasvir than with telaprevir [difference, -29.1% (95%CI: -38.8% to -19.4%)], 
and rash-related events were less frequent with daclatasvir plus pegIFN/RBV 
compared with telaprevir plus pegIFN/RBV. Discontinuations of all 3 agents due 
to an adverse event were more frequent with telaprevir than with daclatasvir, 
whereas discontinuations due to lack of efficacy were more frequent with 
daclatasvir, due, in part, to differences in futility criteria. 
Applications
Although all-oral regimens have become the new standard of care in chronic 
HCV management - for which daclatasvir is currently approved for the treatment 
of HCV GT1, GT3, and GT4 infections (approvals vary by country) - pegIFN/
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RBV-based therapies will remain a potentially important treatment option in 
such settings as low-income countries or possible for patients who have failed 
DAA-only therapies. The results of this study and other studies support the role 
of daclatasvir as an effective and well-tolerated component of interferon-free, 
all-oral HCV regimens across multiple genotypes.
Terminology
SVR12/24, sustained virologic response [HCV-RNA < lower limit of quantitation 
(LLOQ)] at posttreatment week 12/24; Relapse, undetectable HCV-RNA at the 
end of treatment followed by confirmed HCV-RNA ≥ LLOQ at any follow-up 
visit. In the daclatasvir group, treatment futility, which mandated discontinuation 
of all study drugs, was defined as (1) virologic breakthrough (> 1-log10 increase 
in HCV-RNA over nadir or confirmed HCV-RNA ≥ LLOQ after confirmed 
undetectable HCV-RNA while on treatment beginning at week 2 of therapy); (2) 
week 12 HCV-RNA >1000 IU/mL; or (3) week 24 HCV-RNA ≥ LLOQ. In the 
telaprevir group, treatment futility was defined per prescribing information as 
HCV-RNA > 1000 IU/mL (at weeks 4 or 12) or HCV-RNA detectable confirmed (at 
week 24). 
Peer-review
The arena within which HCV is treated has moved at a very rapid pace over 
the past 5 years. The range of DAA options has expanded since telaprevir and 
boceprevir were the first protease inhibitors to become available. While globally, 
the world is focused on DAAs as the treatments of choice for HCV, these drugs 
are expensive and not all countries will be in a position to treat infection vs 
disease. In fact, some first-world countries are currently only treating patients 
with advanced disease due to the cost of these drugs. The authors make this 
point nicely and rightly state that there may be a place for IFN based anti-viral 
strategies for the management and treatment of HCV.
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